GATA3 immunohistochemical expression in invasive urothelial carcinoma

被引:21
|
作者
Mohammed, Kareem Hosny [1 ]
Siddiqui, Momin T. [1 ]
Cohen, Cynthia [1 ]
机构
[1] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
关键词
GATA3; expression; Genitourinary tumors; IHC; GENE-EXPRESSION; BREAST; DIFFERENTIATION; PROSTATE; MARKERS;
D O I
10.1016/j.urolonc.2016.04.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: GATA binding protein 3 (GATA3) is a transcription factor, which belongs to a distinct family of tumor suppressor genes. It is involved in human cancer cell growth and differentiation, and plays an important role in cell proliferation and apoptosis. Although, its expression has been reported in various cancers, there are limited data in genitourinary malignancies. Recent studies found GATA3 to be a sensitive marker for urothelial carcinoma (UC) and associated with prognostic pathologic features. Its level of expression was found to be an independent factor predicting cancer recurrence. Methods and materials: In this article, immunohistochemical evaluation of GATA3 expression in genitourinary malignancies (invasive UC, renal cell carcinoma, and prostatic adenocarcinomas) was performed. Results: GATA3 was positive in 56/79 (70.8%) of invasive UC, and was negative in all renal cell carcinoma and prostatic adenocarcinomas. The pattern of GATA3 staining, when positive, was intensely nuclear within the clusters of malignant cells. No cytoplasmic staining was noted. Negative controls were all negative. High GATA3 expression was associated with larger tumor size in invasive UC (3.19cm vs. 1.65cm, P = 0.01). GATA3 expression did not correlate with other clinicopathologic parameters in UC. Conclusions: This data suggest that GATA3 is a sensitive marker in confirming invasive UC, and may be helpful in differentiating it from metastatic tumors of renal and prostatic origin. Furthermore, strong GATA3 expression was noted to have an effect on tumor size in patients with UC. (C) 2016 Elsevier Inc. All rights reserved
引用
收藏
页码:432.e9 / 432.e13
页数:5
相关论文
共 50 条
  • [41] HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains
    Zhu, Xiaolin
    Chan, Emily
    Turski, Michelle L.
    Mendez, Carlos Espinosa
    Hsu, Sarah C.
    Kumar, Vipul
    Shipp, Chase
    Jindal, Tanya
    Chang, Kevin
    Onodera, Courtney
    Devine, W. Patrick
    Grenert, James P.
    Stohr, Bradley A.
    Ding, Chien-Kuang Cornelia
    Stachler, Matthew D.
    Quigley, David A.
    Feng, Felix Y.
    Chu, Carissa E.
    Porten, Sima P.
    Chou, Jonathan
    Friedlander, Terence W.
    Koshkin, Vadim S.
    ONCOLOGIST, 2024, 29 (08): : e1094 - e1097
  • [42] A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma
    Leivo, Mariah Z.
    Elson, Paul J.
    Tacha, David E.
    Delahunt, Brett
    Hansel, Donna E.
    PATHOLOGY, 2016, 48 (06) : 543 - 549
  • [43] Utility of GATA3 Immunohistochemistry for Diagnosis of Metastatic Breast Carcinoma in Cytology Specimens
    Braxton, David R.
    Cohen, Cynthia
    Siddiqui, Momin T.
    DIAGNOSTIC CYTOPATHOLOGY, 2015, 43 (04) : 271 - 277
  • [44] GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas
    Cimino-Mathews, Ashley
    Subhawong, Andrea P.
    Illei, Peter B.
    Sharma, Rajni
    Halushka, Marc K.
    Vang, Russell
    Fetting, John H.
    Park, Ben Ho
    Argani, Pedram
    HUMAN PATHOLOGY, 2013, 44 (07) : 1341 - 1349
  • [45] GATA3 amplification is associated with high grade disease in non-invasive urothelial bladder cancer but unrelated to patient prognosis
    Plage, Henning
    Frericks, Adrian
    Hofbauer, Sebastian
    Furlano, Kira
    Weinberger, Sarah
    Rossner, Florian
    Schallenberg, Simon
    Elezkurtaj, Sefer
    Lennartz, Maximilian
    Marx, Andreas
    Samtleben, Henrik
    Fisch, Margit
    Rink, Michael
    Slojewski, Marcin
    Kaczmarek, Krystian
    Ecke, Thorsten
    Koch, Stefan
    Simon, Ronald
    Sauter, Guido
    Zecha, Henrik
    Weischenfeldt, Joachim
    Klatte, Tobias
    Minner, Sarah
    Horst, David
    Schlomm, Thorsten
    Kluth, Martina
    BMC UROLOGY, 2025, 25 (01):
  • [46] GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin
    Bezerra, Stephania Martins
    Lotan, Tamara Levin
    Faraj, Sheila Friedrich
    Karram, Sarah
    Sharma, Rajni
    Schoenberg, Mark
    Bivalacqua, Trinity J.
    Netto, George Jabboure
    HUMAN PATHOLOGY, 2014, 45 (08) : 1682 - 1687
  • [47] GATA3 as a putative marker of breast cancer metastasisA retrospective immunohistochemical study
    De Lara, Shahin
    Parris, Toshima Z.
    Ronnerman, Elisabeth Werner
    Helou, Khalil
    Kovacs, Aniko
    BREAST JOURNAL, 2018, 24 (02): : 184 - 188
  • [48] Epigenetic deregulation of GATA3 in neuroblastoma is associated with increased GATA3 protein expression and with poor outcomes
    Almutairi, Bader
    Charlet, Jessica
    Dallosso, Anthony R.
    Szemes, Marianna
    Etchevers, Heather C.
    Malik, Karim T. A.
    Brown, Keith W.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [49] Dedifferentiated Melanoma With Expression of Cytokeratin and GATA3 in a Patient With History of Breast Carcinoma
    Alkhasawneh, Ahmad
    Nassri, Ammar
    John, Ivy
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2019, 41 (07) : 502 - 504
  • [50] The pitfalls of an invasive non-neuroendocrine GATA3- and TTF1+ urothelial carcinoma
    Pini, Giacomo Maria
    Giordano, Monica
    Colecchia, Maurizio
    Patriarca, Carlo
    PATHOLOGICA, 2024, 116 (05) : 335 - 337